Literature DB >> 6641085

Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin.

U K Walle, T Walle, S A Bai, L S Olanoff.   

Abstract

Our aim was to determine possible stereoselectivity in the plasma binding of propranolol. Equilibrium dialysis with plasma from seven healthy subjects and a deuterium-labeled pseudoracemate of propranolol was used. Plasma binding of the propranolol enantiomers differed with the unbound fraction of (-)-propranolol (22 +/- 2%; mean +/- SE) being smaller than that of (+)-propranolol (25.3 +/- 1.9%). The (-)/(+)-propranolol ratio for the unbound fraction, a measure of the stereoselectivity, was 0.86 +/- 0.02. There was an inverse correlation between the unbound (-)/(+)-propranolol ratio in individual subjects and overall binding of (+/-)-propranolol, indicating greater stereoselectivity at higher total binding. To assess the site of the stereoselective binding to plasma proteins, the binding of (+)- and (-)-propranolol to human alpha 1-acid glycoprotein (AGP) and human serum albumin (HSA) was examined. The binding to AGP was stereoselective for (-)-propranolol with a (-)/(+)-propranolol ratio for the unbound fraction of 0.79 +/- 0.01, whereas (+)-propranolol was bound to a greater extent to HSA with a (-)/(+)-propranolol ratio for the unbound fraction of 1.07 +/- 0.01. Although these results demonstrate opposite stereoselectivity in the binding of (+)- and (-)-propranolol to AGP and HSA, the stereoselective binding of (-)-propranolol to AGP predominates in plasma. This stereoselective plasma binding of the (-)-enantiomer of propranolol could limit the access of this more active enantiomer to beta-receptors or other active sites. The uptake of propranolol by red blood cells was not stereoselective.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6641085     DOI: 10.1038/clpt.1983.240

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Stereoselective binding of propranolol in the elderly.

Authors:  P Colangelo; M Chandler; R Blouin; P McNamara
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 2.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

3.  A high-performance liquid chromatographic assay for the enantiomers of bevantolol in human plasma.

Authors:  S E Rose; E J Randinitis
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

4.  Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.

Authors:  T Kaila; E Iisalo; A Lehtonen; H Saarimaa
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

Review 5.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

6.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.

Authors:  M S Lennard; P R Jackson; S Freestone; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

7.  Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance.

Authors:  H R Ochs; P Hajdú; D J Greenblatt
Journal:  Klin Wochenschr       Date:  1986-07-15

8.  Stereoselective ring oxidation of propranolol in man.

Authors:  T Walle; U K Walle; M J Wilson; T C Fagan; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers.

Authors:  U K Walle; T C Fagan; M J Topmiller; E C Conradi; T Walle
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

10.  Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins.

Authors:  G Bastian; S Urien; F Brée; P Jolliet; I Rocher; O Crambes; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.